Published in Am J Hum Genet on May 02, 2001
In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect (2004) 2.85
Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect (2003) 2.36
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med (2008) 1.97
Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect (2006) 1.81
Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet (2008) 1.76
A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology (2009) 1.67
Childhood brain tumors, residential insecticide exposure, and pesticide metabolism genes. Environ Health Perspect (2010) 1.62
Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Relation between methylmercury exposure and plasma paraoxonase activity in inuit adults from Nunavik. Environ Health Perspect (2011) 1.48
Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J (2003) 1.30
Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med (2009) 1.24
Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol (2008) 1.21
PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero. Environ Health Perspect (2010) 1.21
Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ Health Perspect (2009) 1.14
Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect (2009) 1.13
Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A (2004) 1.09
Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact (2010) 1.09
Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.07
Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci (2012) 1.07
Molecular haplotyping by linking emulsion PCR: analysis of paraoxonase 1 haplotypes and phenotypes. Nucleic Acids Res (2005) 1.06
A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph Lateral Scler (2008) 1.02
Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology (2012) 0.99
Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1). Environ Health Perspect (2005) 0.96
The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal (2011) 0.95
Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican-American mothers and children. Environ Mol Mutagen (2011) 0.94
Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med (2010) 0.94
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol (2010) 0.93
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics (2013) 0.91
Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure. Environ Int (2013) 0.88
Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res (2012) 0.88
Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease. J Lipids (2012) 0.87
Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin Med Res (2007) 0.86
Dynamic variation in allele-specific gene expression of Paraoxonase-1 in murine and human tissues. Hum Mol Genet (2008) 0.85
Altered lipid peroxidation markers are related to post-traumatic stress disorder (PTSD) and not trauma itself in earthquake survivors. Eur Arch Psychiatry Clin Neurosci (2015) 0.83
Association between paraoxonase gene and stroke in the Han Chinese population. BMC Med Genet (2013) 0.83
Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res (2012) 0.83
Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch Med Sci (2013) 0.83
Novel associations of nonstructural Loci with paraoxonase activity. J Lipids (2012) 0.83
Protective effect of paraoxonase 1 gene variant Gln192Arg in age-related macular degeneration. Am J Ophthalmol (2009) 0.82
Prognostic value of paraoxonase 1 in patients undergoing coronary artery bypass grafting surgery. Med Sci Monit (2014) 0.82
Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine. Neuropsychiatr Dis Treat (2013) 0.80
Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. J Lipid Res (2014) 0.80
Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children's environmental health. Curr Opin Pediatr (2015) 0.79
Biomarkers of sensitivity and exposure in Washington state pesticide handlers. Adv Exp Med Biol (2010) 0.79
Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids Health Dis (2013) 0.79
Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. J Cell Mol Med (2009) 0.79
Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging (2010) 0.79
Relationship between PON1L55M and Q192R gene polymorphisms and high APO B/APO A-I ratios. Indian J Clin Biochem (2009) 0.79
Association of Paraoxonase 1 Gene Polymorphisms With the Risk of Hepatitis B Virus-related Liver Diseases in a Guangxi Population: A Case-control Study. Medicine (Baltimore) (2015) 0.78
Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. Eur J Clin Pharmacol (2013) 0.78
Frequency distribution of the single-nucleotide -108C/T polymorphism at the promoter region of the PON1 gene in Asian Indians and its relationship with coronary artery disease. J Community Genet (2011) 0.78
Association between genetic polymorphisms and carotid atherosclerosis in patients treated with radiotherapy for nasopharyngeal carcinoma. Radiat Oncol (2015) 0.78
Paraoxonase 1 (PON1) C/T-108 association with longitudinal mean arterial blood pressure. Am J Hypertens (2012) 0.77
Role of genetic changes in the progression of cardiovascular diseases. Int J Biomed Sci (2011) 0.77
Association of -108 C>T PON1 polymorphism with polycystic ovary syndrome. Biomed Rep (2013) 0.77
Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact (2016) 0.76
Methylmercury exposure, PON1 gene variants and serum paraoxonase activity in Eastern James Bay Cree adults. J Expo Sci Environ Epidemiol (2014) 0.76
Association between Serum Paraoxonase 1 Activities (PONase/AREase) and L55M Polymorphism in Risk of Female Infertility. Avicenna J Med Biotechnol (2015) 0.75
Alzheimer's Disease and Paraoxonase 1 (PON1) Gene Polymorphisms. Open Biochem J (2017) 0.75
Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environ Int (2017) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
Atherosclerosis. Nature (2000) 15.95
Alternative poly(A) site selection in complex transcription units: means to an end? Nucleic Acids Res (1997) 5.64
Point mutations in AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. Nucleic Acids Res (1990) 4.20
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest (1998) 3.34
Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J (1953) 3.33
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest (1995) 3.23
The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet (1993) 2.88
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet (1996) 2.57
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet (1993) 2.12
Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr (2000) 2.07
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol (2000) 1.94
Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics (1999) 1.88
Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics (2000) 1.79
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest (1997) 1.71
Genetic polymorphism and interethnic variability of plasma paroxonase activity. J Med Genet (1976) 1.61
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol (1998) 1.59
Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol (1997) 1.58
Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos (2000) 1.56
Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol (2000) 1.53
Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics (2001) 1.46
Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem (1989) 1.42
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet (1988) 1.38
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
On the genetics of the human serum paraoxonase (EC 3.1.1.2). Hum Genet (1979) 1.27
Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation (2000) 1.22
Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett (1995) 1.22
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact (1993) 1.14
Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem J (1973) 1.13
Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis (2000) 1.12
Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis (1999) 1.12
Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol (1997) 1.12
Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health (1993) 1.10
A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis (2000) 1.09
Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun (1997) 1.09
Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest (1996) 1.08
Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2000) 1.03
Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem (2000) 1.00
Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol (2000) 0.95
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem (2000) 0.95
Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. J Lipid Res (1999) 0.95
Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes (2000) 0.94
The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B (1985) 0.94
Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos (1998) 0.86
Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics (1999) 0.86
Further evidence for the concept of bovine plasma arylesterase as a lipoprotein. Biochem J (1975) 0.85
Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics (2000) 0.85
Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke (1998) 0.84
A SAF binding site in the promoter region of human gamma-fibrinogen gene functions as an IL-6 response element. J Immunol (2000) 0.82
Analysis of the serum paraoxonase/arylesterase polymorphism in some Sudanese families. Prog Clin Biol Res (1986) 0.82
Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism. Neurotoxicology (1998) 0.79
Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med (1998) 0.78
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
Research ethics. Research practice and participant preferences: the growing gulf. Science (2011) 3.27
The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet (1993) 2.88
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet (1996) 2.57
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
Purification of a leucine-specific binding protein from Escherichia coli. Biochem Biophys Res Commun (1970) 2.09
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol (2000) 1.94
Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics (1999) 1.88
Xylose isomerase from Escherichia coli. Characterization of the protein and the structural gene. J Biol Chem (1984) 1.82
Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics (2000) 1.79
Binding assays for amino acids. The utilization of a cystine binding protein from Escherichia coli for the determination of acid-soluble cystine in small physiological samples. J Biol Chem (1974) 1.74
Biosynthesis of bacterial glycogen. Primary structure of Escherichia coli ADP-glucose synthetase as deduced from the nucleotide sequence of the glg C gene. J Biol Chem (1983) 1.73
Renaturation and identification of periplasmic proteins in two-dimensional gels of Escherichia coli. J Biol Chem (1982) 1.69
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet (1997) 1.68
Resolution of the multiplicity of the glutamate and aspartate transport systems of Escherichia coli. J Biol Chem (1977) 1.65
Genetic association studies: genes in search of diseases. Neurology (2001) 1.65
Purification and properties of a ribose-binding protein from Escherichia coli. J Biol Chem (1974) 1.62
A multichamber equilibrium dialysis apparatus. Anal Biochem (1972) 1.61
MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med (2008) 1.57
Regulation of Glutamine Transport in Escherichia coli. J Bacteriol (1975) 1.51
Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry (1991) 1.46
Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics (2001) 1.46
A binding protein for L-glutamine and its relation to active transport in E. coli. Arch Biochem Biophys (1971) 1.35
Expression of the Escherichia coli xylose isomerase gene in Saccharomyces cerevisiae. Appl Environ Microbiol (1987) 1.35
Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol (1990) 1.32
Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet (1999) 1.30
Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet (1983) 1.27
The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact (1999) 1.26
Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry (1994) 1.24
The amino acid sequence of D-ribose-binding protein from Escherichia coli K12. J Biol Chem (1983) 1.24
Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology (1998) 1.24
Effect of bending strain on the torsion elastic constant of DNA. J Mol Biol (1996) 1.23
Anticipation in familial leukemia. Am J Hum Genet (1996) 1.23
Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett (1995) 1.22
Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet (1984) 1.17
Monte Carlo simulations of supercoiling free energies for unknotted and trefoil knotted DNAs. Biophys J (1995) 1.14
The role of ribose-binding protein in transport and chemotaxis in Escherichia coli K12. Arch Biochem Biophys (1977) 1.14
A simple preparative polyacrylamide disc gel electrophoresis apparatus: purification of three branched-chain amino acid binding proteins from Escherichia coli. Anal Biochem (1973) 1.13
Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health (1993) 1.10
Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact (2010) 1.09
Interactions of a glutamate-aspartate binding protein with the glutamate transport system of Escherichia coli. J Biol Chem (1975) 1.07
A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet (2000) 1.05
Purification and properties of a periplasmic glutamate-aspartate binding protein from Escherichia coli K12 strain W3092. J Biol Chem (1975) 1.05
Construction of biosensors using a gold-binding polypeptide and a miniature integrated surface plasmon resonance sensor. Biosens Bioelectron (1998) 1.04
Interaction of chloroquine with linear and supercoiled DNAs. Effect on the torsional dynamics, rigidity, and twist energy parameter. Biochemistry (1988) 1.03
Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res Mol Brain Res (1994) 1.03
Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol (1994) 1.03
Biosynthesis of bacterial glycogen. VII. Purification and properties of the adenosine diphosphoglucose pyrophosphorylase of Rhodospirillium rubrum. J Biol Chem (1969) 1.02
Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol (1996) 1.01
Sequence of a Drosophila DNA segment that functions in Saccharomyces cerevisiae and its regulation by a yeast promoter. Nucleic Acids Res (1983) 1.01
Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord (1998) 0.99
Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. Mol Chem Neuropathol (1997) 0.98
Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. J Pediatr (1993) 0.96
Dynamics and structures of DNA: long-range effects of a 16 base-pair (CG)8 sequence on secondary structure. Biopolymers (1993) 0.96
High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice. Am J Pathol (1996) 0.95
Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology (2008) 0.94
Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radic Biol Med (2013) 0.93
Effect of ethidium binding and superhelix density on the apparent supercoiling free energy and torsion constant of pBR322 DNA. Biophys Chem (1994) 0.91
Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. J Toxicol Environ Health (1997) 0.90
Reconstitution of binding protein-dependent ribose transport in spheroplasts of Escherichia coli K-12. Arch Biochem Biophys (1979) 0.90
Structural organization of the human PON1 gene. Genomics (1996) 0.90
Autosomal dominant thrombocytopenia: incomplete megakaryocyte differentiation and linkage to human chromosome 10. Blood (2000) 0.90
Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics (1997) 0.89
Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet (1999) 0.89
Genetic linkage analysis of prostate cancer families to Xq27-28. Hum Hered (2001) 0.89
Segregation and linkage analysis of a quantitative versus a qualitative trait in large pedigrees. Genet Epidemiol (1997) 0.89
Cystine: binding protein assay. Methods Enzymol (1987) 0.88
Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol (1998) 0.87
Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics (2000) 0.85
Binding protein-dependent active transport in Escherichia coli and Salmonella typhimurium. Methods Enzymol (1986) 0.85
Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy. Hepatology (2000) 0.85
Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol (2000) 0.85
Evidence for genetic influences on smoking in adult women twins. Clin Genet (1995) 0.84
Alzheimer's disease and the family effect. Nat Genet (1994) 0.84
Selective neurotoxicity of COOH-terminal fragments of the beta-amyloid precursor protein. Neurosci Lett (1993) 0.83
Expression of a carboxy-terminal region of the beta-amyloid precursor protein in a heterogeneous culture of neuroblastoma cells: evidence for altered processing and selective neurotoxicity. Brain Res Mol Brain Res (1992) 0.83
Analysis of quantitative risk factors for a common oligogenic disease. Genet Epidemiol (1995) 0.83
Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 0.83
High resolution two-dimensional gel electrophoresis of human erythrocyte membrane proteins. Am J Hum Genet (1982) 0.82
Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res (2001) 0.81
The PON1 gene and detoxication. Neurotoxicology (2000) 0.80
Transgenic animal models for Alzheimer's disease. Ann N Y Acad Sci (1993) 0.80
Complex segregation analysis of LDL peak particle diameter. Genet Epidemiol (1993) 0.80
Impact of family structure on the power of linkage tests using sib-pair methods. Genet Epidemiol (1999) 0.79
Transketolase from human red blood cells. Methods Enzymol (1982) 0.79
Reconstitution of binding protein dependent ribose transport in spheroplasts derived from a binding protein negative Escherichia coli K12 mutant and from Salmonella typhimurium. J Supramol Struct (1980) 0.79
Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate (2001) 0.79
Symposium overview: the role of genetic polymorphism and repair deficiencies in environmental disease. Toxicol Sci (1999) 0.79
Overexpression of a C-terminal portion of the beta-amyloid precursor protein in mouse brains by transplantation of transformed neuronal cells. Exp Neurol (1994) 0.78
Affective disorders and Alzheimer disease: a missing-link hypothesis. Am J Geriatr Psychiatry (2001) 0.78
Microfluidic one-step synthesis of alginate microspheres immobilized with antibodies. J R Soc Interface (2013) 0.78
Neutral amino acid transport during the cell cycle of cultured human lymphocytes. J Cell Physiol (1981) 0.78
Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of beta-amyloid precursor protein. Neurosci Lett (1996) 0.78
Recommended nomenclature system for the paraoxonases. Chem Biol Interact (1999) 0.76
Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. Curr Probl Pediatr (1994) 0.75
Ribose-binding protein from Escherichia coli. Methods Enzymol (1982) 0.75